David Altshuler, Executive Vice President of Global Research and Chief Scientific Officer, has demonstrated a consistent pattern of selling shares in Vertex Pharmaceuticals (VRTX) over the past two years, with no recorded purchases. Since February 2024, Altshuler has executed multiple sales totaling approximately $24.7 million, with the most recent transactions occurring in early 2025. Notable sales include a $1.65 million disposition on March 13, 2025, following a $1.62 million sale on March 10 and a $1.58 million transaction on March 3 of the same year. Earlier in February 2025, he sold shares worth $610,560 and $407,846, alongside larger transactions classified as derivative dispositions (Code F), including a $2.86 million transaction on February 26 and a $1.92 million transaction on February 24.
The selling activity extends back to 2024, with significant sales such as $1.80 million on February 26 and $1.27 million on February 21, often accompanied by derivative transactions. While some filings (Code A) reflect awards or adjustments with no immediate monetary value, the overwhelming trend is one of liquidation, with all 27 recorded transactions involving sales or derivative disposals. Altshuler’s trading history suggests a deliberate reduction in his VRTX holdings, with no indication of accumulation over the observed period. The transactions, spanning multiple months, do not cluster around a single event but instead reflect a sustained divestment strategy.
AI-assisted summary